20.500.12556/RUL-133139 Early Lyme borreliosis in patients treated with tumour necrosis factor-alfa inhibitors The study evaluated the course and outcome of erythema migrans in patients receiving tumour necrosis factor-alpha (TNF-α) inhibitors. Among 4157 adults diagnosed with erythema migrans in the period 2009–2018, 16 (2.6%) patients were receiving TNF-α inhibitors (adalimumab, infliximab, etarnecept, golimumab), often in combination with other immunosuppressants, for rheumatic (13 patients) or inflammatory bowel (three patients) disease. Findings in this group were compared with those in 32 sex- and age-matched immunocompetent patients diagnosed with erythema migrans in the same years. In comparison with the control group, the immunocompromised patients had a shorter incubation period (7 vs. 14 days; p = 0.0153), smaller diameter of erythema migrans (10.5 vs. 15.5 cm; p = 0.0014), and more frequent comorbidities other than immune-mediated diseases (62.5% vs. 25%, p = 0.0269), symptoms/signs of disseminated Lyme borreliosis (18.8% vs. 0%, p = 0.0324), and treatment failure (25% vs. 0%, p = 0.0094). After retreatment with an antibiotic, the clinical course of Lyme borreliosis resolved. Continuing TNF inhibitor treatment during concomitant borrelial infection while using identical approaches for antibiotic treatment as in immunocompetent patients resulted in more frequent failure of erythema migrans treatment in patients receiving TNF inhibitors. However, the majority of treatment failures were mild, and the course and outcome of Lyme borreliosis after retreatment with antibiotics was favourable. Lyme borreliosis immunocompromised host TNF-α inhibitors erythema migrans treatment outcome true false true Angleški jezik Ni določen Članek v reviji 2021-11-12 14:10:20 2021-11-12 14:10:21 2022-09-12 04:15:03 0000-00-00 00:00:00 2019 0 0 13 str. iss. 11, art. 1857 Vol. 8 2019 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.9 2077-0383 10.3390/jcm8111857 6634412 RAZ_Maraspin-Carman_Vera_2019.pdf RAZ_Maraspin-Carman_Vera_2019.pdf 1 DDDF58D65E7A9EE21D7D101F33ABFA47 ac1e5835ea675b84f4fe68dc1b69a9aabdd36d891db6e909aa149f23b9562ddf fea04675-43b9-11ec-abdb-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=150971 https://www.mdpi.com/2077-0383/8/11/1857 1 d46fb2db-43b9-11ec-abdb-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=150970 Medicinska fakulteta 0 0 0